Managing Director (in ch.), NCT Heidelberg
Head: Translational Medical Oncology
Phone: +49 6221 56-6990/-35212
Fax: +49 6221 56-6967
Since April 2018, Professor Stefan Fröhling has been Acting Managing Director of NCT Heidelberg. In addition, he heads the division of Translational Medical Oncology at NCT/DKFZ. Stefan Fröhling’s research aims at providing as many patients as possible with individually tailored cancer treatments. As part of the Precision Oncology Program, much of his work is centered on the development of tools for the comprehensive molecular and functional characterization of individual tumors, and the conception of clinical studies examining the efficacy of modern, molecularly targeted treatment approaches. In addition to his research in the precision oncology field, Stefan Fröhling particularly focuses on the biology of bone and soft-tissue sarcomas as well as acute forms of leukemia.